<DOC>
	<DOCNO>NCT00833391</DOCNO>
	<brief_summary>The purpose study evaluate relative drug concentration achieve different formulation GSK1838262 healthy volunteer .</brief_summary>
	<brief_title>Relative Bioavailability Study GSK1838262 ( Gabapentin Enacarbil )</brief_title>
	<detailed_description>This open-label , randomize , single-dose , five-period , crossover study evaluate relative drug concentration different formulation GSK1838262 healthy volunteer . Four new formulation test current formulation identify promise new formulation development . Each subject participate five dose period period separate least seven day . Blood urine sample collect 36 hour period follow dose administration measure drug concentration .</detailed_description>
	<criteria>healthy , male female subject age 18 65 year old . normal body weight . normal ECG , vital sign lab test . normal kidney function agree use acceptable contraceptive method require . capable give write informed consent . positive blood alcohol urine drug test . positive hepatitis B/C HIV donation 450 mL blood within 56 day . sensitivity gabapentin pregnant lactating female smoker certain medical condition include heart disease , psychiatric disease , gastrointestinal disease , kidney liver dysfunction history seizure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>healthy volunteer</keyword>
	<keyword>formulation</keyword>
	<keyword>bioavailability</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>